53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05673993 (ClinicalTrials.gov) | April 2023 | 29/12/2022 | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome | A Phase ?, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Biological: Telitacicept 80 mg;Biological: Telitacicept 160 mg;Drug: Placebo | RemeGen Co., Ltd. | NULL | Not yet recruiting | 18 Years | 70 Years | All | 375 | Phase 3 | China |